Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids

Ning-Sheng Cai(Integrative Medicine Institute), César Quiroz(Integrative Medicine Institute), Jordi Bonaventura, Alessandro Bonifazi(National Institute on Drug Abuse), Thomas O. Cole(University of Maryland, Baltimore), Julia Purks(Massachusetts General Hospital), Amy S. Billing(University of Maryland, College Park), Ebonie Massey(University of Maryland, College Park), Michael Wagner(University of Maryland, College Park), Eric D. Wish(University of Maryland, College Park), Xavier Guitart(Integrative Medicine Institute), William Rea(Integrative Medicine Institute), Sherry Lam, Estefanía Moreno(Universitat de Barcelona), Verònica Casadó-Anguera(Universitat de Barcelona), Aaron D. Greenblatt(University of Maryland, Baltimore), Arthur E. Jacobson(Chemical Synthesis Lab), Kenner C. Rice(Chemical Synthesis Lab), Vicent Casadó(Universitat de Barcelona), Amy Hauck Newman(National Institute on Drug Abuse), John W. Winkelman(Massachusetts General Hospital), Michael Michaelides, Eric Weintraub(University of Maryland, Baltimore), Nora D. Volkow(National Information Standards Organization), Annabelle M. Belcher(University of Maryland, Baltimore), Sergi Ferré(Integrative Medicine Institute)
Journal of Clinical Investigation
March 26, 2019
Cited by 67Open Access
Full Text

Abstract

Identifying non-addictive opioid medications is a high priority in medical sciences, but μ-opioid receptors mediate both the analgesic and addictive effects of opioids. We found a significant pharmacodynamic difference between morphine and methadone that is determined entirely by heteromerization of μ-opioid receptors with galanin Gal1 receptors, rendering a profound decrease in the potency of methadone. This was explained by methadone's weaker proficiency to activate the dopaminergic system as compared to morphine and predicted a dissociation of therapeutic versus euphoric effects of methadone, which was corroborated by a significantly lower incidence of self-report of "high" in methadone-maintained patients. These results suggest that μ-opioid-Gal1 receptor heteromers mediate the dopaminergic effects of opioids that may lead to a lower addictive liability of opioids with selective low potency for the μ-opioid-Gal1 receptor heteromer, exemplified by methadone.


Related Papers

No related papers found

Powered by citation graph analysis